What type of study is this?

This is a RCT study (also classified as: Observational).

September 5, 2025Open Access

Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors

LHLihaoyun HuangZhujiang Hospital HYHaijun YuShanghai Institute of Materia Medica CZChunyan ZhangShanxi Medical University

Key Points

Microbiome diversity correlates with improved progression-free survival in cancer patients receiving immunotherapy.
Viral status, especially from hepatitis B and human papillomavirus, significantly predicts treatment response rates.
Bacterial enrichment is linked to enhanced survival rates in patients with hepatobiliary and lung cancers.
Multi-microbiome models outperform traditional predictors in forecasting outcomes of immune checkpoint inhibitors.

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, with the microbiome significantly influencing treatment outcomes. Analysis of 4663 studies (2014.01-2024.10) identified 71 eligible randomized controlled trials (RCTs) and cohort studies (41 viral, 30 bacterial). Analyses included subgroup assessments by cancer type, microbial taxa, and ICI regimens. Among 4663 identified studies, 71 met inclusion criteria (41 viral, 30 bacterial). Viral status, particularly hepatitis B virus (HBV) and human papillomavirus (HPV), significantly associated with ORR and DCR. Bacterial enrichment correlated with improved survival in hepatobiliary (OS: HR = 4.33, 95%CI: 2.20–8.50) and lung cancers (PFS: HR = 1.70, 95%CI: 1.04–2.78). Multi-microbiome models demonstrated superior outcome prediction, with microbial diversity correlating with improved PFS (HR = 0.64, 95%CI: 0.42–0.98). Viral status showed cancer-specific associations with SAEs. The microbiome serves as a valuable predictor of ICI outcomes. Future studies should emphasize large-scale RCTs, standardized assessment methods, and host-microbiome interactions.

Ask AI

Helpful

Bookmark

View Full Paper